Maya Thanou: The unseen journey from idea to breakthrough cancer therapy

In this episode of the Research Adventure podcast, Maya shares her journey as the CEO of Apeikon, a company focused on developing activatable nanoparticles for targeted cancer treatment. She discusses the challenges and triumphs of spinning out from King's College London, the importance of stakeholder engagement, and the current status of their clinical trials. Maya also highlights the significance of funding, her advice for pursuing grants, and her vision for the future of precision medicine. The conversation concludes with her reflections on supporting the next generation of academic entrepreneurs and the impact of her work on the world.